The New Biomarker for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC) Based on Public Database Mining.


Journal

BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173

Informations de publication

Date de publication:
2020
Historique:
received: 25 10 2019
revised: 02 03 2020
accepted: 10 03 2020
entrez: 1 5 2020
pubmed: 1 5 2020
medline: 11 2 2021
Statut: epublish

Résumé

To reconstruct the ceRNA biological network of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) and to select an appropriate mRNA as a biomarker that could be used for CESC early diagnosis and prognosis evaluation. We downloaded CESC data from the TCGA public database, and statistical analysis was conducted with the R software to find out differential expressed genes encoding for lncRNAs, miRNAs, and mRNAs. The differentially expressed mRNAs (DEmRNAs) screened in the ceRNA network were analyzed for survival to find the mRNAs with significantly linked to the survival prognosis. These mRNAs were searched in the Pathological Atlas to identify the final appropriate mRNAs. Differential expression analysis revealed 773 lncRNAs, 94 miRNAs, and 2466 mRNAs. Survival analysis of DEmRNAs in the ceRNA network indicated that ADGRF4, ANXA8L1, HCAR3, IRF6, and PDE2A (

Identifiants

pubmed: 32351997
doi: 10.1155/2020/5478574
pmc: PMC7174939
doi:

Substances chimiques

Biomarkers, Tumor 0
Neoplasm Proteins 0
RNA, Neoplasm 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5478574

Informations de copyright

Copyright © 2020 Hao Ding et al.

Déclaration de conflit d'intérêts

The authors declare that there are no conflicts of interest.

Références

Novartis Found Symp. 2002;247:91-101; discussion 101-3, 119-28, 244-52
pubmed: 12539951
J Med Chem. 2017 Mar 9;60(5):2037-2051
pubmed: 28165743
Cell Mol Life Sci. 2018 Feb;75(3):467-484
pubmed: 28840253
Nat Med. 2015 Nov;21(11):1253-61
pubmed: 26540387
Nature. 2014 Feb 20;506(7488):371-5
pubmed: 24390348
Vascul Pharmacol. 2019 Mar;114:145-156
pubmed: 29425892
Cancer Lett. 2017 Sep 10;403:305-317
pubmed: 28687357
Bioorg Med Chem Lett. 2013 Dec 15;23(24):6522-7
pubmed: 24189054
Nat Genet. 2018 Jun;50(6):783-789
pubmed: 29785014
Bioinformatics. 2008 Jan 15;24(2):282-4
pubmed: 18006545
Cancer Genet. 2016 Oct;209(10):463-473
pubmed: 27810075
Oncol Rep. 2013 Apr;29(4):1275-84
pubmed: 23381931
Nucleic Acids Res. 2003 Jan 1;31(1):258-61
pubmed: 12519996
J Pharmacol Exp Ther. 2018 Apr;365(1):179-188
pubmed: 29440309
Cell Prolif. 2019 Jul;52(4):e12628
pubmed: 31038266
J Cell Physiol. 2018 Sep;233(9):6822-6831
pubmed: 29319172
Mov Disord. 2018 Mar;33(3):482-488
pubmed: 29392776
J Cell Physiol. 2019 Aug;234(10):18837-18848
pubmed: 30916406
J Pathol. 2008 Dec;216(4):387-93
pubmed: 18853439
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Nucleic Acids Res. 2012 Jan;40(Database issue):D565-70
pubmed: 22123736
FEBS J. 2014 Aug;281(16):3609-24
pubmed: 24942287
J Cell Physiol. 2020 Mar;235(3):2464-2477
pubmed: 31502679
Nature. 2015 Jul 23;523(7561):459-462
pubmed: 26131930
Curr Opin Oncol. 2018 Sep;30(5):323-329
pubmed: 29994902
Int J Technol Assess Health Care. 2015 Jan;31(3):171-80
pubmed: 26179276
Int J Cancer. 2018 Aug 15;143(4):944-957
pubmed: 29516499
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Mol Carcinog. 2019 Apr;58(4):554-564
pubmed: 30520151
Cell. 2018 Apr 5;173(2):283-285
pubmed: 29625045
Asian Pac J Cancer Prev. 2018 Feb 26;19(2):319-324
pubmed: 29479954
J Nucl Med. 2016 Sep;57(9):1388-95
pubmed: 27103022
J Natl Compr Canc Netw. 2019 Jan;17(1):64-84
pubmed: 30659131
Cell. 2011 Aug 5;146(3):353-8
pubmed: 21802130
Oncol Lett. 2018 Jun;15(6):8965-8972
pubmed: 29805632
Bioinformatics. 2016 Jun 1;32(11):1716-23
pubmed: 26826716
Cancer Med. 2015 Oct;4(10):1573-82
pubmed: 26256448
Oncotarget. 2017 Dec 13;9(4):4798-4813
pubmed: 29435142
Arch Pathol Lab Med. 2018 Jun;142(6):688-692
pubmed: 29848034
Asian Pac J Cancer Prev. 2013;14(9):5101-5
pubmed: 24175783
Cancer. 2017 Jul 1;123(13):2404-2412
pubmed: 28464289
Hum Mol Genet. 2006 Apr 15;15 Spec No 1:R17-29
pubmed: 16651366

Auteurs

Hao Ding (H)

Department of Gynecology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

Xiao-Xing Xiong (XX)

Central Laboratory, Renmin hospital, Wuhan University, 430006, China.

Guan-Lan Fan (GL)

Department of Gynecology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

Yue-Xiong Yi (YX)

Department of Gynecology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

Yu-Rou Chen (YR)

Department of Gynecology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

Jing-Tao Wang (JT)

Department of Gynecology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

Wei Zhang (W)

Department of Gynecology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH